Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Thomas

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Annals of Surgical Oncology|August 30, 2008
Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy (HIPEC)Fabienne Thomas, Gwenaël Ferron, Amélie Gesson-Paute, et al.
Bulletin Du Cancer|December 2, 2009
[Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer]Gwénaël Ferron, Alejandra Martinez, Eliane Mery, et al.
JCO Oncology Practice|December 3, 2024
Large-Scale DPD Testing Should Be More Than an OptionMarie-Christine Etienne-Grimaldi, Bernard Royer, Manon Launay, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2025
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancyPaul Vilquin, Yves Medard, Fabienne Thomas, et al.
Annals of Surgical Oncology|October 19, 2007
Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental studyAmélie Gesson-Paute, Gwenael Ferron, Fabienne Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Serum cystatin C is a better marker of topotecan clearance than serum creatinineAntje Hoppe, Sophie Séronie-Vivien, Fabienne Thomas, et al.
International Journal of Colorectal Disease|March 23, 2015
Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiencyCarole Dhelens, Agnès Bonadona, Fabienne Thomas, et al.
Clinical Pharmacology and Therapeutics|June 18, 2026
Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?Jeanne Petit, Julien Plenecassagnes, Aurelie Brice, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2021
Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidinesMaud Maillard, Audrey Eche-Gass, Mony Ung, et al.
Cancer Research|October 14, 2021
Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal CancerMarie Malier, Khaldoun Gharzeddine, Marie-Hélène Laverriere, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Annals of Surgical Oncology|August 30, 2008
Increased tissue diffusion of oxaliplatin during laparoscopically assisted versus open heated intraoperative intraperitoneal chemotherapy (HIPEC)Fabienne Thomas, Gwenaël Ferron, Amélie Gesson-Paute, et al.
Bulletin Du Cancer|December 2, 2009
[Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer]Gwénaël Ferron, Alejandra Martinez, Eliane Mery, et al.
JCO Oncology Practice|December 3, 2024
Large-Scale DPD Testing Should Be More Than an OptionMarie-Christine Etienne-Grimaldi, Bernard Royer, Manon Launay, et al.
Cancer Chemotherapy and Pharmacology|January 2, 2025
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancyPaul Vilquin, Yves Medard, Fabienne Thomas, et al.
Annals of Surgical Oncology|October 19, 2007
Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental studyAmélie Gesson-Paute, Gwenael Ferron, Fabienne Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Serum cystatin C is a better marker of topotecan clearance than serum creatinineAntje Hoppe, Sophie Séronie-Vivien, Fabienne Thomas, et al.
International Journal of Colorectal Disease|March 23, 2015
Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiencyCarole Dhelens, Agnès Bonadona, Fabienne Thomas, et al.
Clinical Pharmacology and Therapeutics|June 18, 2026
Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?Jeanne Petit, Julien Plenecassagnes, Aurelie Brice, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2021
Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidinesMaud Maillard, Audrey Eche-Gass, Mony Ung, et al.
Cancer Research|October 14, 2021
Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal CancerMarie Malier, Khaldoun Gharzeddine, Marie-Hélène Laverriere, et al.
Pageof 9